Recent Posts
Podcast•Feb 25, 2026•52 min
Reprogramming Cancer From Within
In this episode, Dr. Aaron Vinnie shares his journey from a leukemia survivor to a Columbia University hematology‑oncology researcher, advocating a shift from traditional cytotoxic chemotherapy to precision strategies that rewire malignant blood cells. He explains how hematologic cancers stem from dysregulated stem‑cell programs and highlights the promise of targeting epigenetic regulators and cell‑surface markers to distinguish healthy marrow regeneration from refractory disease. Vinnie also discusses recent advances such as mutation‑specific small‑molecule inhibitors and CAR‑T therapy, while emphasizing the critical role of basic science and sustained funding in enabling these paradigm‑changing treatments.
By The Bio Report
Podcast•Feb 11, 2026•23 min
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
The episode explores EnGene's experimental gene therapy, detalimogene, for treating non‑muscle invasive bladder cancer, a condition affecting half a million new patients annually. Ron Cooper, EnGene's CEO, explains how the therapy uses a non‑viral vector to deliver a dual payload...
By The Bio Report
Podcast•Feb 4, 2026•38 min
Reprogramming T Cells to Cross the Brain’s Border
In this episode, host and guest Michael Roberts, co‑founder and CEO of Adaptin Bio, discuss the difficulty of delivering biologic therapies across the blood‑brain barrier for glioblastoma patients. Roberts explains Adaptin’s platform, which reprograms a patient’s own T cells to...
By The Bio Report
Podcast•Jan 28, 2026•46 min
A Billion Dollar Bet on AI-First Drug Development
In this episode, Marc Tessier‑Lavigne, co‑founder and CEO of Xaira, explains how the company is using an end‑to‑end AI platform to overhaul drug discovery by tackling three core bottlenecks: target selection, molecule design, and patient stratification. Xaira trains high‑dimensional "virtual...
By The Bio Report
Podcast•Jan 21, 2026•37 min
Finding New Targets on the Surface of Misfolded Proteins
In this episode of The Bio Report, host and guests discuss Immuto Scientific’s novel approach to drug discovery that targets disease‑specific protein conformations rather than genetic sequences. CEO Faraz Choudhury explains how the company’s AI‑driven structural surfaceomics platform maps the...
By The Bio Report
Podcast•Jan 7, 2026•29 min
An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages
In this episode, Daniel Levine interviews Valerie Daggett, founder and CEO of AltPep, about the company's strategy to detect and treat Alzheimer's disease at its earliest stage by targeting toxic α‑sheet oligomers with synthetic peptide therapeutics and companion diagnostics. Daggett...
By The Bio Report
Podcast•Dec 10, 2025•37 min
Determining the Cause and Severity of Sepsis with a Point-of-Care Test
In this episode of The Bio Report, host Daniel Levine interviews Tim Sweeney, CEO of Inflammatix, about the company's TriVerity point‑of‑care test that rapidly distinguishes bacterial from viral infections and gauges immune response severity in sepsis patients. Sweeney explains how...
By The Bio Report